Current look at the most promising proteomic and glycomic biomarkers of bladder cancer

Abstract

Background Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential. Methods We performed an online search in PubMed/Medline, Scopus, and Web of Science databases to find relevant studies published in English up until May 2023. If applicable, we set the AUC threshold to 0.90 and sensitivity/specificity (SN/SP) to 90%. Findings Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics. Cholinesterase shows promise in progression-free survival. BLCA-4, ORM-1 along with HTRA1 in the detection of BC. Matrix metallopeptidase 9 exhibits potential for stratification of muscle-invasive subtypes with high negative predictive value for aggressive phenotypes. Distinguishing non-muscle invasive subtypes benefits from Keratin 17. Neu5Gc-modified UMOD glycoproteins pose potential in BC diagnosis, while fibronectin, laminin-5, collagen type IV, and lamprey immunity protein in early detection of BC.

Prognostic and Predictive Potential of CCL5 Expression in Muscle-Invasive Bladder Cancer Patients

“…Adjuvant chemotherapy was effective in lymph node-positive MIBC patients regardless of their p53 status [ 7 ]. Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics [ 8 ]. However, there are still no applied prognostic and/or predictive protein biomarkers for chemotherapy response in MIBC patients.…”